These results indicate that the Predict tool could still be useful to identify groups of patients who had a higher vs lower risk of death from a second cancer, although it may not provide an accurate estimation of the absolute risk, particularly in women diagnosed with a second estrogen receptor–positive cancer. The gene discussed is ESR1; the disease is cancer.